Identification of the DREAM transcriptional repression complex as a mediator of the differential response observed in EpCAM+/CD44+/CD166+ as compared to EpCAM+/CD44neg/CD166neg colon cancer cells following in vivo chemotherapy with irinotecan (CPT-11). Here, EPCAM is linked to malignant colon neoplasm.